These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26758075)

  • 1. Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(II)-based compounds with antitumoral activity.
    de Camargo MS; da Silva MM; Correa RS; Vieira SD; Castelli S; D'Anessa I; De Grandis R; Varanda E; Deflon VM; Desideri A; Batista AA
    Metallomics; 2016 Feb; 8(2):179-92. PubMed ID: 26758075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding.
    da Silva MM; de Camargo MS; Correa RS; Castelli S; De Grandis RA; Takarada JE; Varanda EA; Castellano EE; Deflon VM; Cominetti MR; Desideri A; Batista AA
    Dalton Trans; 2019 Oct; 48(39):14885-14897. PubMed ID: 31555783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ru/Fe bimetallic complexes: Synthesis, characterization, cytotoxicity and study of their interactions with DNA/HSA and human topoisomerase IB.
    Takarada JE; Guedes APM; Correa RS; Silveira-Lacerda EP; Castelli S; Iacovelli F; Deflon VM; Batista AA; Desideri A
    Arch Biochem Biophys; 2017 Dec; 636():28-41. PubMed ID: 29107586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium(II) Phosphine/Mercapto Complexes: Their in Vitro Cytotoxicity Evaluation and Actions as Inhibitors of Topoisomerase and Proteasome Acting as Possible Triggers of Cell Death Induction.
    Ribeiro GH; Guedes APM; de Oliveira TD; de Correia CRSTB; Colina-Vegas L; Lima MA; Nóbrega JA; Cominetti MR; Rocha FV; Ferreira AG; Castellano EE; Teixeira FR; Batista AA
    Inorg Chem; 2020 Oct; 59(20):15004-15018. PubMed ID: 32997499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
    Castelli S; Vassallo O; Katkar P; Che CM; Sun RW; Desideri A
    Arch Biochem Biophys; 2011 Dec; 516(2):108-12. PubMed ID: 22033340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.
    da Silva MM; Ribeiro GH; de Camargo MS; Ferreira AG; Ribeiro L; Barbosa MIF; Deflon VM; Castelli S; Desideri A; Corrêa RS; Ribeiro AB; Nicolella HD; Ozelin SD; Tavares DC; Batista AA
    Inorg Chem; 2021 Sep; 60(18):14174-14189. PubMed ID: 34477373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization, X-ray structure and in vitro antimycobacterial and antitumoral activities of Ru(II) phosphine/diimine complexes containing the "SpymMe2" ligand, SpymMe2=4,6-dimethyl-2-mercaptopyrimidine.
    do Nascimento FB; Von Poelhsitz G; Pavan FR; Sato DN; Leite CQ; Selistre-de-Araújo HS; Ellena J; Castellano EE; Deflon VM; Batista AA
    J Inorg Biochem; 2008 Sep; 102(9):1783-9. PubMed ID: 18614238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB.
    Soren BC; Babu Dasari J; Ottaviani A; Messina B; Andreotti G; Romeo A; Iacovelli F; Falconi M; Desideri A; Fiorani P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antitumor activity of a novel carbonyl ruthenium compound, the ct-[RuCl(CO)(dppb)(bipy)]PF-6[dppb=1,4-bis(diphenylphosphine)butane and bipy=2,2'-bipyridine].
    Carnizello AP; Barbosa MI; Martins M; Ferreira NH; Oliveira PF; Magalhães GM; Batista AA; Tavares DC
    J Inorg Biochem; 2016 Nov; 164():42-48. PubMed ID: 27613330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A derivative of the natural compound kakuol affects DNA relaxation of topoisomerase IB inhibiting the cleavage reaction.
    Castelli S; Vieira S; D'Annessa I; Katkar P; Musso L; Dallavalle S; Desideri A
    Arch Biochem Biophys; 2013 Feb; 530(1):7-12. PubMed ID: 23262316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
    Gopal YN; Jayaraju D; Kondapi AK
    Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.
    Seol Y; Zhang H; Agama K; Lorence N; Pommier Y; Neuman KC
    Mol Cancer Ther; 2015 Nov; 14(11):2552-9. PubMed ID: 26351326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A natural anticancer agent thaspine targets human topoisomerase IB.
    Castelli S; Katkar P; Vassallo O; Falconi M; Linder S; Desideri A
    Anticancer Agents Med Chem; 2013 Feb; 13(2):356-63. PubMed ID: 22931416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the cytotoxic and genotoxic potential of the carbonyl ruthenium(II) compound, ct-[RuCl(CO)(dppb)(bipy)]PF
    Carnizello AP; Alves JM; Pereira DE; Campos JCL; Barbosa MIF; Batista AA; Tavares DC
    J Appl Toxicol; 2019 Apr; 39(4):630-638. PubMed ID: 30460706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric inhibition of topoisomerase I by pinostrobin: Molecular docking, spectroscopic and topoisomerase I activity studies.
    Jadaun A; Subbarao N; Dixit A
    J Photochem Photobiol B; 2017 Feb; 167():299-308. PubMed ID: 28122297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase Iα: in vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines.
    Tabassum S; Zaki M; Afzal M; Arjmand F
    Eur J Med Chem; 2014 Mar; 74():509-23. PubMed ID: 24508781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.